S. 2305 · 118th Congress · Health

Biosimilar Red Tape Elimination Act

Died in committee762 words Introduced Jul 13, 2023 · Latest action Jul 13, 2023

How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedJul 13, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill removes certain requirements for biosimilars to be designated as interchangeable. (Biosimilars that are designated as interchangeable may be substituted for the reference product at a pharmacy without a new prescription, depending on state pharmacy laws.)

Specifically, the bill establishes a presumption that an approved biosimilar is interchangeable with the reference product without the need for additional evidence from the manufacturer, and it removes the applicable exclusivity periods for a first interchangeable biosimilar (i.e., a product that is the first interchangeable biosimilar to be approved with respect to the reference product).

The Food and Drug Administration (FDA) may require a manufacturer of a biosimilar to conduct a safety study with respect to switching or alternating between the biosimilar and the reference product, but only after the FDA briefs certain members of specified congressional committees to explain why the study is necessary.

Congressional Research Service · summary of “Introduced in Senate” version · Jul 13, 2023

Who lobbies on it

20 organizations · 75 filings · Q3 2023–Q4 2024

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Pharmaceutical Research and Manufacturers of America 6 of 6 quarters
    “H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 456: Fairness in Orphan Drug Exclusivity Act H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the…”

    Q4 2024 filing · $31.0M lobbying spend in 2024, all issues

  2. Amgen Inc 6 of 6 quarters
    “Issues related to drug pricing reform Changes to Public law 117-1769 Inflation Reduction Act Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830…”

    Q4 2024 filing · $11.6M lobbying spend in 2024, all issues

  3. Biotechnology Innovation Organization 6 of 6 quarters
    “340B Drug Discount Program ---H.R.8574: 340B Affording Care for Communities and Ensuring a Strong Safety-net Act ---S.1133: 340B Accountability Act ---Executive Order on Access to Affordable Life-Saving Medications ---Program Implementation & Oversight ---PROTECT 340B Act ---SUSTAIN 340B Act Accelerated Approval…”

    Q4 2024 filing · $6.7M lobbying spend in 2024, all issues

17 more organizations, every filingPROUpgrade

Organizations that named S. 2305 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

2 actions · newest first
  1. Jul 13, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. Jul 13, 2023Introduced in Senate